Cerebrospinal fluid amyloid-β 2-42 is decreased in Alzheimer’s, but not in frontotemporal dementia

• Published in: Journal of Neural Transmission Vol. 119; no. 7; pp. 805 - 813
• Main Authors: Bibl, Mirko, Gallus, Marion, Welge, Volker, Esselmann, Hermann, Wolf, Stefanie, Rüther, Eckart, Wiltfang, Jens
• Format: Journal Article
• Language: English
• Published: Vienna Springer Vienna 01.07.2012
• Subjects: Aged; Aged, 80 and over; Alzheimer Disease - cerebrospinal fluid; Alzheimer Disease - diagnosis; Alzheimer's disease; Amyloid beta-Peptides - cerebrospinal fluid; beta -Amyloid; biomarkers; Biomarkers - cerebrospinal fluid; Cerebrospinal fluid; Dementia disorders; Dementias - Original; Dementias - Original Article; Depressive Disorder - cerebrospinal fluid; Depressive Disorder - diagnosis; Diagnosis, Differential; Differential diagnosis; Disease control; Female; Frontotemporal dementia; Frontotemporal Dementia - cerebrospinal fluid; Frontotemporal Dementia - diagnosis; Humans; Immunoprecipitation; Male; Medicine; Medicine & Public Health; Middle Aged; Neurodegenerative diseases; Neurology; Neurosciences; Peptide Fragments - cerebrospinal fluid; Psychiatry; Cerebrospinal fluid; Aminoterminally truncated; Frontotemporal dementia; Amyloid-β peptides; Alzheimer’s dementia; Aβ2-42
• ISSN: 0300-9564; 1435-1463
• DOI: 10.1007/s00702-012-0801-3

Alzheimer’s dementia (AD) and frontotemporal dementias (FTD) are common and their clinical differential diagnosis may be complicated by overlapping symptoms, which is why biomarkers may have an important role to play. Cerebrospinal fluids (CSF) Aβ2-42 and 1-42 have been shown to be similarly decreased in AD, but 1-42 did not display sufficient specificity for exclusion of other dementias from AD. The objective of the present study was to clarify the diagnostic value of Aβ2-42 peptides for the differential diagnosis of AD from FTD. For this purpose, 20 non-demented disease controls (NDC), 22 patients with AD and 17 with FTD were comparatively analysed by a novel sequential aminoterminally and carboxyterminally specific immunoprecipitation protocol with subsequent Aβ-SDS-PAGE/immunoblot, allowing the quantification of peptides 1-38 ox , 2-40 and 2-42 along with Aβ 1-37, 1-38, 1-39, 1-40, 1-40 ox and 1-42. CSF Aβ1-42 was decreased in AD as compared to NDC, but not to FTD. In a subgroup of the patients analyzed, the decrease of Abeta2-42 in AD was evident as compared to both NDC and FTD. Aβ1-38 was decreased in FTD as compared to NDC and AD. For differentiating AD from FTD, Aβ1-42 demonstrated sufficient diagnostic accuracies only when combined with Aβ1-38. Aβ2-42 yielded diagnostic accuracies of over 85 % as a single marker. These accuracy figures could be improved by combining Aβ2-42 to Aβ1-38. Aβ2-42 seems to be a promising biomarker for differentiating AD from other degenerative dementias, such as FTD.